Here, immunohistochemistry confirmed that HCC tumoral cells were able to produce higher levels of EPO, under lenvatinib, than non-tumoral hepatocytes in the cirrhotic liver (Fig. 2). The gene discussed is EPO; the disease is hepatocellular carcinoma.